| |
GENESIS RESEARCH AND DEVELOPMENT CORPORATION LIMITED Company Summary |
|
| Genesis Research is a New Zealand-based biotechnology company, listed on the New Zealand and Australian stock exchanges. Since Genesis was established in 1994, it has built a broad therapeutic development platform targeting immune disorders and cancer and is developing RNAi therapeutics. Genesis has undertaken ten clinical trials in New Zealand and other countries, including seven at phase II, in collaboration with a number of international companies including Immunex (now Amgen) and Corixa (now GSK). Genesis has also worked with CSL, EvoGenix, Jurox and other Australian groups. Genesis has 4 issued patents on FGFR5 and several other patents pending that make claims to the therapeutic use of FGFR5 or FGFR5 antagonists in a variety of disorders. |
|
|
|
 |
Headquarters |
P.O. Box 50, Auckland 1140 |
 |
| |
|
New Zealand |
|
|
Telephone |
+64 9 373 5600 |
|
|
Fax |
+64 9 373 5601 |
|
|
Principal Sector |
Health & Pharm |
|
|
Principal Industry |
Biotechnology |
|
|
Listed |
2000/09/22 |
|
|
Homepage |
www.genesis.co.nz |
|
| |
|
|
|
| Stock Exchange | Stock Code |  ASX:GEN | GEN | | | NZSE | GEN | | | | | | | |
|
| |
NEWS |
 |
|
|
